M
8.60
0.48 (5.91%)
| Penutupan Terdahulu | 8.12 |
| Buka | 8.10 |
| Jumlah Dagangan | 428,740 |
| Purata Dagangan (3B) | 485,379 |
| Modal Pasaran | 692,221,696 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.61 |
| Harga / Jualan (P/S) | 23.67 |
| Harga / Buku (P/B) | 228.30 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -2,159.71% |
| EPS Cair (TTM) | -2.31 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 176.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 244.35% |
| Nisbah Semasa (MRQ) | 1.52 |
| Aliran Tunai Operasi (OCF TTM) | -104.58 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.25 M |
| Pulangan Atas Aset (ROA TTM) | -37.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -216.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | MeiraGTx Holdings plc | Menurun | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.38 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 24.27% |
| % Dimiliki oleh Institusi | 60.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sanofi | 30 Sep 2025 | 12,197,737 |
| Knoll Capital Management, Llc | 30 Sep 2025 | 1,250,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (Chardan Capital, 306.98%) | Beli |
| Median | 29.00 (237.21%) | |
| Rendah | 16.00 (RBC Capital, 86.05%) | Beli |
| Purata | 26.00 (202.33%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 8.42 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 20.00 (132.56%) | Beli | 7.57 |
| Chardan Capital | 14 Nov 2025 | 35.00 (306.98%) | Beli | 8.19 |
| 11 Nov 2025 | 35.00 (306.98%) | Beli | 8.90 | |
| RBC Capital | 14 Nov 2025 | 16.00 (86.05%) | Beli | 8.19 |
| Piper Sandler | 11 Nov 2025 | 30.00 (248.84%) | Beli | 8.90 |
| Raymond James | 21 Oct 2025 | 29.00 (237.21%) | Beli | 9.26 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference |
| 13 Nov 2025 | Pengumuman | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results |
| 10 Nov 2025 | Pengumuman | MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology |
| 07 Oct 2025 | Pengumuman | MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |